Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting ...Middle East

55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical trial CAMBRIDGE, Mass., Nov. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX),...

Hence then, the article about leap therapeutics to present updated data from the distinguish study of dkn 01 plus tislelizumab and preclinical data in colorectal cancer models at the sitc annual meeting was published today ( Monday 07/11/2022 - 04:09 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting )

Also on site :

• Man arrested on suspicion of fatal shooting in Huntington Beach
• Danish authorities banned from using Bluetooth at work – media
• ‘China Beach’ and ‘CSI’ Star Marg Helgenberger Is a Stunning Strawberry Blonde at 67